Sandeep Nayak
Johns Hopkins University · Johns Hopkins School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sandeep Nayak as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:16 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07503002 · Shortened LSD Intervention for Major Depressive DisorderJohns Hopkins University · not yet recruiting · Major Depression Moderate, Major Depression Severe, Major Depression · principal investigator
- Ph2NCT06810765 · Trifecta Research StudyJohns Hopkins University · withdrawn · PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma · principal investigator
- Ph1NCT06407635 · A Study of Psilocybin for PTSDJohns Hopkins University · active not recruiting · Post Traumatic Stress Disorder · principal investigator
- Ph2NCT06067737 · Outpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderJohns Hopkins University · recruiting · Opioid Use Disorder · principal investigator
- Ph2NCT06005662 · Inpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderJohns Hopkins University · withdrawn · Opioid Use Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:16 UTC. The ranking covers the 200 most relevant of 57 PubMed records, and a shared surname and initials can bring in a namesake. All 57 on PubMed
- Remdesivir for the Treatment of Covid-19 - Final Report.N Engl J Med · 20205,332 citationsRCR 287.3
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.N Engl J Med · 20211,413 citationsRCR 83.9
- Homologous and Heterologous Covid-19 Booster Vaccinations.N Engl J Med · 2022490 citationsRCR 29.0
- Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.Cell Rep Med · 2022154 citationsRCR 8.1
- Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.Lancet Respir Med · 2021145 citationsRCR 6.9
- Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.Lancet Respir Med · 202298 citationsRCR 6.1
- 87 citationsRCR 2.9
- Effect of dietary supplementation of probiotic and vitamin C on the immune response of Indian major carp, Labeo rohita (Ham.).Fish Shellfish Immunol · 200776 citationsRCR 3.1
- 73 citationsRCR 2.2
- Patient navigation pathway and barriers to treatment seeking in cancer in India: a qualitative inquiry.Cancer Epidemiol · 201369 citationsRCR 2.8